Virological Markers in Epstein-Barr Virus-Associated Diseases

Area of Science:

• Virology
• Oncology
• Immunology

Background:

• Epstein-Barr virus (EBV) infects over 95% of the global population, establishing lifelong persistence.
• While often asymptomatic, EBV is linked to cancers like lymphoma and carcinoma, and potentially multiple sclerosis.
• The absence of a vaccine necessitates the development of clinical virological markers for disease management.

Purpose of the Study:

• To review the clinical utility of existing and emerging virological markers for Epstein-Barr virus (EBV)-associated diseases.
• To highlight the importance of these markers in managing EBV-related malignancies and immune-mediated inflammatory conditions.

Main Methods:

• Review of current literature on virological markers for EBV.
• Analysis of established markers like serological and molecular assays for nasopharyngeal carcinoma.
• Exploration of emerging markers including EBV DNA load, methylome, strain diversity, and viral miRNA.

Main Results:

• Serological and molecular markers are established for nasopharyngeal carcinoma.
• Blood EBV DNA load is valuable for preventing post-transplant lymphoproliferative disorders and is explored in lymphomas.
• Next-generation sequencing enables investigation of novel biomarkers such as the EBV methylome and viral miRNA.

Conclusions:

• Virological markers are crucial for clinical management of EBV-associated diseases.
• Evaluating current and novel markers for EBV-related cancers and immune disorders remains a significant challenge.
• Further research into advanced biomarkers like the EBV methylome and miRNA is warranted.